GENOME-BASED THERAPEUTICS FOR PERSONALIZED TREATMENT OF MULTIDRUG-RESISTANT CANCERS

Abstract

Background: Multidrug-resistant (MDR) cancers are a significant challenge in cancer research because of tumor heterogeneity, genomic instability, and resistance to chemotherapy and preferred therapies. This is because standard treatment therapy often does not manage to clear preexisting tumor groups, resulting into a relapse of the disease and adverse prognosis.

Objective: This paper discusses the merits of genome-based therapeutic approaches to design customized therapy of multidrug-resistant tumours based on genomic profiling, specific genome editing, and targeted molecular treatments.

Methodology: Recent studies in the field of translational oncology and preclinical cancer models were used to compare and contrast CRISPR-based genome editing, RNA therapies, immunogenomic targeting, epigenetic modulation, and biomarker-directed precision therapies.

Findings: Genome-based treatment strategies showed better sensitivity to treatment in resistant cancer models and exhibited higher specificity on the tumors. Targeting associated with CRISPR has decreased drug efflux activity by about 40-60 per cent, explicitly, RNA interference, and epigenetics therapies have restored chemosensitivity, and stopped tumor growth. Similarly, personal immunogenomic-based interventions positively augmented immune activity and efficacy of targeting tumors, leading to almost 45-70% of tumor removal in multiple preclinical investigations.

Conclusion: Genome-based therapeutics is a revolutionary approach to personalized therapy of multi-drug-resistant cancers. Nevertheless, optimization of delivery, heterogeneity of tumors, off target effects, and scalability to clinic are the key issues of the future translational application.